Item 5.03 Amendment to Articles of Incorporation or Bylaws; Changes in Fiscal Year.
As reported below in Item 5.07 the stockholders of Halozyme Therapeutics, Inc. (the “Company”) approved an amendment to the Company's Certificate of Incorporation to increase the Company's authorized number of shares of common stock from 200,000,000 shares to 300,000,000 shares (the “Charter Amendment”). The Company's Board of Directors approved the Charter Amendment on February 13, 2019, subject to approval by the Company's stockholders.
An Amended and Restated Certificate of Incorporation, reflecting the Charter Amendment, was filed with the Secretary of State of the State of Delaware on May 2, 2019, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference. A summary of the Charter Amendment was included in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 22, 2019.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 2, 2019, the Company held its Annual Meeting of Stockholders. Of the 145,300,534 shares of the Company's common stock outstanding as of the record date, 125,783,100 shares were represented at the annual meeting.
The stockholders considered four proposals at the meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 22, 2019. The number of votes cast for and against (or withheld) and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below.
Proposal 1:
Election of three Class III directors to hold office for a three-year term expiring at the 2022 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:
|
|
|
|
|
|
|
|
Names
|
|
Votes For
|
|
Withheld
|
|
Broker Non-Votes
|
Jeffrey W. Henderson
|
|
101,090,907
|
|
1,310,664
|
|
23,381,529
|
Connie L. Matsui
|
|
100,720,626
|
|
1,680,945
|
|
23,381,529
|
Helen I. Torley
|
|
101,785,053
|
|
616,518
|
|
23,381,529
|
Each of the foregoing candidates were elected and each received affirmative votes from more than a majority of the outstanding shares.
Proposal 2:
The advisory vote on the compensation of the Company's named executive officers was as follows:
|
|
|
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Abstain
|
|
Broker Non-Votes
|
92,074,144
|
|
10,263,491
|
|
63,936
|
|
23,381,529
|
The foregoing proposal was approved.
Proposal 3:
The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019 was as follows:
|
|
|
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Abstain
|
|
Broker Non-Votes
|
125,054,022
|
|
657,474
|
|
71,604
|
|
—
|
The foregoing proposal was approved.
Proposal 4:
The vote to approve an amendment to the Company’s Certificate of Incorporation to increase its authorized number of shares of common stock from 200,000,000 to 300,000,000 was as follows:
|
|
|
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Abstain
|
|
Broker Non-Votes
|
111,437,037
|
|
14,088,195
|
|
257,868
|
|
—
|
The foregoing proposal was approved.